Shamburg News · 8-K filed Nov 12, 2026, 4:16 PM EST
AnaptysBio Reports Fiscal First Quarter 2027 Financial Results and Business Update
ANAB · ANAPTYSBIO, INC
- Earnings
- Materiality: high
On November 12, 2026, AnaptysBio reported financial results for the three months ended September 30, 2026, with collaboration revenue of $30.3 million, down from $76.3 million a year earlier, and net income from continuing operations of $3.9 million, or $0.13 basic and $0.11 diluted per share. The company also reported cash, cash equivalents and investments of $153.0 million as of September 30, 2026, and provided an update on the GSK and Tesaro litigation, with a judgment anticipated in calendar Q4 2026 or Q1 2027. The filing also included a Quimilza FDA target action date of December 12, 2026.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-458461.
Written from the filing by Shamburg Markets. Figures are as reported by the company.